Range
49.78 - 57.07
Vol / Avg.
250.4K/694.5K
Div / Yield
-
52 Wk
29.5 - 73.8
Mkt Cap
2.6B
Payout Ratio
-
Open
49.78
P/E
-
EPS
-0.45
Shares
46.1M
Outstanding
46.1M
Total Float
34.6M
Benzinga - Jul 16, 2021, 11:10AM
Benzinga - Jul 13, 2021, 1:02PM
Benzinga - Jul 12, 2021, 7:45AM
Benzinga - Jul 12, 2021, 7:44AM
Benzinga - Jul 12, 2021, 5:46AM
Benzinga - Jul 12, 2021, 5:41AM
Benzinga - Jul 1, 2021, 11:59AM
Benzinga - Jun 30, 2021, 1:34PM
Benzinga - Jun 17, 2021, 12:34PM
Benzinga - Jun 17, 2021, 12:02PM
Benzinga - Jun 17, 2021, 9:28AM
Sector: Health Care.Industry: Biotechnology
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS
(EXPECTED)2021-08-23
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
VERVVerve Therapeutics-5.81%2.6B

Verve Therapeutics Frequently Asked Questions

Q

How do I buy Verve Therapeutics (VERV) stock?

A

You can purchase shares of Verve Therapeutics (NASDAQ: VERV) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Verve Therapeutics's (VERV) competitors?

A

Other companies in Verve Therapeutics’s space includes: Zentalis Pharmaceuticals (NASDAQ:ZNTL), Burning Rock Biotech (NASDAQ:BNR), Centessa Pharmaceuticals (NASDAQ:CNTA), Prothena Corp (NASDAQ:PRTA) and OPKO Health (NASDAQ:OPK).

Q

What is the target price for Verve Therapeutics (VERV) stock?

A

The latest price target for Verve Therapeutics (NASDAQ: VERV) was reported by William Blair on July 12, 2021. The analyst firm set a price target for 92.00 expecting VERV to rise to within 12 months (a possible 65.59% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Verve Therapeutics (VERV)?

A

The stock price for Verve Therapeutics (NASDAQ: VERV) is $55.56 last updated Today at 8:00:01 PM.

Q

Does Verve Therapeutics (VERV) pay a dividend?

A

There are no upcoming dividends for Verve Therapeutics.

Q

When is Verve Therapeutics (NASDAQ:VERV) reporting earnings?

A
Verve Therapeutics’s Q2 earnings are confirmed for after-market on August 23, 2021.
Q

Is Verve Therapeutics (VERV) going to split?

A

There is no upcoming split for Verve Therapeutics.

Q

What sector and industry does Verve Therapeutics (VERV) operate in?

A

Verve Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.